Hydrochlorothiazide and triamterene with sustained-release oxprenolol in the treatment of hypertension.
A single-blind, three-way Latin square crossover study without wash-out periods was performed in a general practice. Thirty moderately hypertensive patients were studied to compare the antihypertensive effect of 160 mg sustained-release oxprenolol once daily, 25 mg hydrochlorothiazide/50 mg triamterene once daily or a combination of the two preparations once daily, each treatment being given for 1 month. Blood pressure control was significantly better with the combination than with either agent used separately. Pulse rates, as expected, were lower when sustained-release oxprenolol was taken either alone or in the combination. Adverse events led to withdrawal in 1 patient only. Otherwise, all treatments were well tolerated and compliance was excellent. Renal function tests indicated a slight increase in creatinine, urate and urea levels after the treatments which included hydrochlorothiazide compared with oxprenolol alone, although the results were of no clinical significance.
D000368:Aged; D003404:Creatinine / Q000097:blood; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006852:Hydrochlorothiazide / Q000627:therapeutic use*; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D007677:Kidney Function Tests; D008297:Male; D008875:Middle Aged; D010096:Oxprenolol / Q000008:administration & dosage / Q000627:therapeutic use*; D011188:Potassium / Q000097:blood; D011897:Random Allocation; D014223:Triamterene / Q000627:therapeutic use*; D014508:Urea / Q000097:blood; D014527:Uric Acid / Q000097:blood
D006852:Hydrochlorothiazide; D014527:Uric Acid; D010096:Oxprenolol; D014508:Urea; D003404:Creatinine; D011188:Potassium; D014223:Triamterene